
List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4808421/publications.pdf Version: 2024-02-01



TOMASZ CUZIK

#	Article	IF	CITATIONS
1	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. European Heart Journal, 2022, 43, 1059-1103.	1.0	111
2	Current progress in clinical, molecular, and genetic aspects of adult fibromuscular dysplasia. Cardiovascular Research, 2022, 118, 65-83.	1.8	14
3	Central role of c-Src in NOX5- mediated redox signalling in vascular smooth muscle cells in human hypertension. Cardiovascular Research, 2022, 118, 1359-1373.	1.8	26
4	MMP-2 knockdown blunts age-dependent carotid stiffness by decreasing elastin degradation and augmenting eNOS activation. Cardiovascular Research, 2022, 118, 2385-2396.	1.8	14
5	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. European Heart Journal, 2022, 43, 1033-1058.	1.0	80
6	Systemic administration of glucocorticoids, cardiovascular complications and mortality in patients hospitalised with COVID-19, SARS, MERS or influenza: A systematic review and meta-analysis of randomised trials. Pharmacological Research, 2022, 176, 106053.	3.1	10
7	Animal models and animal-free innovations for cardiovascular research: current status and routes to be explored. Consensus document of the ESC Working Group on Myocardial Function and the ESC Working Group on Cellular Biology of the Heart. Cardiovascular Research, 2022, 118, 3016-3051.	1.8	30
8	Old, but gold? Not the case for the immune system when promoting systemic ageing. Cardiovascular Research, 2022, 118, e14-e16.	1.8	1
9	Immune System and Microvascular Remodeling in Humans. Hypertension, 2022, 79, 691-705.	1.3	30
10	European Society of Cardiology guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 1—epidemiology, pathophysiology, and diagnosis. Cardiovascular Research, 2022, 118, 1385-1412.	1.8	27
11	Long-Term Treatment with the Combination of Rivaroxaban and Aspirin in Patients with Chronic Coronary or Peripheral Artery Disease: Outcomes During the Open Label Extension of the COMPASS trial. European Heart Journal - Cardiovascular Pharmacotherapy, 2022, 8, 786-795.	1.4	6
12	Contributions of obesity to kidney health and disease: insights from Mendelian randomization and the human kidney transcriptomics. Cardiovascular Research, 2022, 118, 3151-3161.	1.8	17
13	ESC guidance for the diagnosis and management of cardiovascular disease during the COVID-19 pandemic: part 2—care pathways, treatment, and follow-up. Cardiovascular Research, 2022, 118, 1618-1666.	1.8	32
14	Neuroimmune cardiovascular interfaces control atherosclerosis. Nature, 2022, 605, 152-159.	13.7	86
15	Breast cancer chemotherapy induces vascular dysfunction and hypertension through a NOX4-dependent mechanism. Journal of Clinical Investigation, 2022, 132, .	3.9	11
16	Kidney omics in hypertension: from statistical associations to biological mechanisms and clinical applications. Kidney International, 2022, 102, 492-505.	2.6	11
17	Rationale and Design for the LOnger-term effects of SARS-CoV-2 INfection on blood Vessels And blood pRessure (LOCHINVAR): an observational phenotyping study. Open Heart, 2022, 9, e002057.	0.9	3
18	Pleiotropic actions of factor Xa inhibition in cardiovascular prevention: mechanistic insights and implications for anti-thrombotic treatment. Cardiovascular Research, 2021, 117, 2030-2044.	1.8	27

#	Article	IF	CITATIONS
19	Endothelial function in cardiovascular medicine: a consensus paper of the European Society of Cardiology Working Groups on Atherosclerosis and Vascular Biology, Aorta and Peripheral Vascular Diseases, Coronary Pathophysiology and Microcirculation, and Thrombosis. Cardiovascular Research, 2021, 117, 29-42.	1.8	164
20	Efficacy and safety of rivaroxaban plus aspirin in women and men with chronic coronary or peripheral artery disease. Cardiovascular Research, 2021, 117, 942-949.	1.8	15
21	Rivaroxaban Plus Aspirin in Obese and Overweight Patients With Vascular Disease in the COMPASS Trial. Journal of the American College of Cardiology, 2021, 77, 511-525.	1.2	11
22	ls systemic inflammation a missing link between periodontitis and hypertension? Results from two large populationâ€based surveys. Journal of Internal Medicine, 2021, 289, 532-546.	2.7	24
23	Reply. Journal of Hypertension, 2021, 39, 383.	0.3	0
24	Lowâ€grade chronic inflammation and immune alterations in childhood and adolescent cancer survivors: A contribution to accelerated aging?. Cancer Medicine, 2021, 10, 1772-1782.	1.3	15
25	The year in basic vascular biology research: from mechanoreceptors and neutrophil extracellular traps to smartphone data and omics. Cardiovascular Research, 2021, 117, 1814-1822.	1.8	4
26	A call to action for new global approaches to cardiovascular disease drug solutions. European Heart Journal, 2021, 42, 1464-1475.	1.0	29
27	Periodontal therapy and treatment of hypertension-alternative to the pharmacological approach. A systematic review and meta-analysis. Pharmacological Research, 2021, 166, 105511.	3.1	22
28	Immune spleen cells attenuate the inflammatory profile of the mesenteric perivascular adipose tissue in obese mice. Scientific Reports, 2021, 11, 11153.	1.6	3
29	Uncovering genetic mechanisms of hypertension through multi-omic analysis of the kidney. Nature Genetics, 2021, 53, 630-637.	9.4	37
30	Echocardiography Predictors of Survival in Hypertensive Patients With Left Ventricular Hypertrophy. American Journal of Hypertension, 2021, 34, 636-644.	1.0	7
31	Progress in cardiac research: from rebooting cardiac regeneration to a complete cell atlas of the heart. Cardiovascular Research, 2021, 117, 2161-2174.	1.8	23
32	BS25â€TAM receptor AXL loss regulates smooth muscle cell differentiation and accelerates atherosclerosis in mice. , 2021, , .		0
33	Cardiovascular and Renal Risk Factors and Complications Associated With COVID-19. CJC Open, 2021, 3, 1257-1272.	0.7	18
34	Impact of acute total occlusion of the culprit artery on outcome in NSTEMI based on the results of a large national registry. BMC Cardiovascular Disorders, 2021, 21, 297.	0.7	6
35	Reply. Journal of the American College of Cardiology, 2021, 77, 2757.	1.2	0
36	IL-15 and IL-7: keys to dysregulated inflammation in acute coronary syndromes. Cardiovascular Research, 2021, 117, 1806-1808.	1.8	3

#	Article	IF	CITATIONS
37	Role of inflammatory chemokines in hypertension. , 2021, 223, 107799.		70
38	A Call to Action for New Global Approaches to Cardiovascular Disease Drug Solutions. Circulation, 2021, 144, 159-169.	1.6	18
39	Mortality Benefit of Rivaroxaban Plus Aspirin in Patients With Chronic Coronary or Peripheral Artery Disease. Journal of the American College of Cardiology, 2021, 78, 14-23.	1.2	31
40	Molecular imaging of cardiovascular inflammation. British Journal of Pharmacology, 2021, 178, 4216-4245.	2.7	5
41	Leaders in Cardiovascular Research: Joseph C. Wu. Cardiovascular Research, 2021, 117, e126-e128.	1.8	1
42	Mounting Pressure of Periodontitis. Hypertension, 2021, 78, 552-554.	1.3	2
43	Selective Inhibition of the C-Domain of ACE (Angiotensin-Converting Enzyme) Combined With Inhibition of NEP (Neprilysin): A Potential New Therapy for Hypertension. Hypertension, 2021, 78, 604-616.	1.3	7
44	Skeletonized vs Pedicled Internal Mammary Artery Graft Harvesting in Coronary Artery Bypass Surgery. JAMA Cardiology, 2021, 6, 1042.	3.0	35
45	Dynamic sustainability, a look at the philosophy behind one of Spain's flagship cardiovascular institutes, the CNIC. Cardiovascular Research, 2021, 117, e151-e155.	1.8	1
46	Leaders in Cardiovascular Research: Nilesh J. Samani. Cardiovascular Research, 2021, 117, e144-e146.	1.8	0
47	IL-18 (Interleukin-18) Produced by Renal Tubular Epithelial Cells Promotes Renal Inflammation and Injury During Deoxycorticosterone/Salt-Induced Hypertension in Mice. Hypertension, 2021, 78, 1296-1309.	1.3	22
48	Therapeutic targeting of inflammation in hypertension: from novel mechanisms to translational perspective. Cardiovascular Research, 2021, 117, 2589-2609.	1.8	25
49	Access to dental care and blood pressure profiles in adults with high socioeconomic status. Journal of Periodontology, 2021, , .	1.7	5
50	Periodontitis as an inflammatory trigger in hypertension: From basic immunology to clinical implications. Kardiologia Polska, 2021, 79, 1206-1214.	0.3	3
51	Nanoparticle theranostics in cardiovascular inflammation. Seminars in Immunology, 2021, 56, 101536.	2.7	13
52	Periodontitis is associated with hypertension: a systematic review and meta-analysis. Cardiovascular Research, 2020, 116, 28-39.	1.8	200
53	Chanzyme TRPM7 protects against cardiovascular inflammation and fibrosis. Cardiovascular Research, 2020, 116, 721-735.	1.8	78
54	High Leukocyte Count and Risk of Poor Outcome After Subarachnoid Hemorrhage: AÂMeta-Analysis. World Neurosurgery, 2020, 135, e541-e547.	0.7	9

#	Article	IF	CITATIONS
55	E-vaporating benefits of e-vaping. European Heart Journal, 2020, 41, 2484-2486.	1.0	4
56	Effects of Interleukin-1Î ² Inhibition on Blood Pressure, Incident Hypertension, and Residual Inflammatory Risk. Hypertension, 2020, 75, 477-482.	1.3	69
57	Leaders in Cardiovascular Research: Eric Olson. Cardiovascular Research, 2020, 116, e54-e55.	1.8	0
58	Response by Siedlinski et al to Letters Regarding Article, "White Blood Cells and Blood Pressure: A Mendelian Randomization Study― Circulation, 2020, 142, e191-e192.	1.6	2
59	Picking up the pace: another record high impact factor for Cardiovascular Research. Cardiovascular Research, 2020, 116, e165-e168.	1.8	3
60	Hypertension and renin-angiotensin system blockers are not associated with expression of angiotensin-converting enzyme 2 (ACE2) in the kidney. European Heart Journal, 2020, 41, 4580-4588.	1.0	41
61	CardioScape-II: the need to map cardiovascular funding patterns in Europe. Cardiovascular Research, 2020, 116, 879-881.	1.8	Ο
62	The swan song of dying cells. Cardiovascular Research, 2020, 116, e90-e92.	1.8	2
63	Endothelial dysfunction in COVID-19: a position paper of the ESC Working Group for Atherosclerosis and Vascular Biology, and the ESC Council of Basic Cardiovascular Science. Cardiovascular Research, 2020, 116, 2177-2184.	1.8	331
64	Nox1/4 inhibition exacerbates age dependent perivascular inflammation and fibrosis in a model of spontaneous hypertension. Pharmacological Research, 2020, 161, 105235.	3.1	19
65	Leaders in Cardiovascular Research: Filippo Crea. Cardiovascular Research, 2020, 116, e159-e161.	1.8	Ο
66	Active gingival inflammation is linked to hypertension. Journal of Hypertension, 2020, 38, 2018-2027.	0.3	32
67	Leaders in Cardiovascular Research: Stephan Achenbach. Cardiovascular Research, 2020, 116, e143-e145.	1.8	Ο
68	Cardiovascular Research at the frontier of biomedical science. Cardiovascular Research, 2020, 116, e83-e86.	1.8	3
69	Periodontitis and Hypertension: Is the Association Causal?. High Blood Pressure and Cardiovascular Prevention, 2020, 27, 281-289.	1.0	44
70	Cytokines at the Interplay Between Asthma and Atherosclerosis?. Frontiers in Pharmacology, 2020, 11, 166.	1.6	22
71	From Rags to Riches. Hypertension, 2020, 75, 930-934.	1.3	13
72	White Blood Cells and Blood Pressure. Circulation, 2020, 141, 1307-1317.	1.6	125

#	Article	IF	CITATIONS
73	Oxidative Stress as a Link between Cerebrocardiovascular and Psychiatric Disorders. Oxidative Medicine and Cellular Longevity, 2020, 2020, 1-2.	1.9	2
74	T-Cell–Derived miRNA-214 Mediates Perivascular Fibrosis in Hypertension. Circulation Research, 2020, 126, 988-1003.	2.0	59
75	The pathogenic role of coronary microvascular dysfunction in the setting of other cardiac or systemic conditions. Cardiovascular Research, 2020, 116, 817-828.	1.8	46
76	Leaders in Cardiovascular Research: Salim Yusuf. Cardiovascular Research, 2020, 116, e26-e28.	1.8	1
77	Coronary microvascular dysfunction in Cardiovascular Research: Time to turn on the spotlight!. European Heart Journal, 2020, 41, 612-613.	1.0	1
78	COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovascular Research, 2020, 116, 1666-1687.	1.8	1,074
79	Significance of sphingosine-1-phosphate in cardiovascular physiology and pathology. Pharmacological Research, 2020, 156, 104793.	3.1	97
80	Inside the heart of COVID-19. Cardiovascular Research, 2020, 116, e59-e61.	1.8	33
81	Oleacein and Foam Cell Formation in Human Monocyte-Derived Macrophages: A Potential Strategy against Early and Advanced Atherosclerotic Lesions. Pharmaceuticals, 2020, 13, 64.	1.7	15
82	Leaders in Cardiovascular Research: Valentin Fuster. Cardiovascular Research, 2020, 116, e62-e63.	1.8	0
83	Hypertension, the renin–angiotensin system, and the risk of lower respiratory tract infections and lung injury: implications for COVID-19. Cardiovascular Research, 2020, 116, 1688-1699.	1.8	282
84	Binding of SARS-CoV-2 and angiotensin-converting enzyme 2: clinical implications. Cardiovascular Research, 2020, 116, e87-e89.	1.8	33
85	Why do some asthma patients respond poorly to glucocorticoid therapy?. Pharmacological Research, 2020, 160, 105189.	3.1	53
86	Ekonomiczne uzasadnienie swobody sędziowskiej. Studia Iuridica Lublinensia, 2020, 29, 87.	0.2	0
87	Perivascular adipose tissue as the secret behind resistance to atherosclerosis exhibited by the human internal mammary artery. Kardiologia Polska, 2020, 78, 1194-1196.	0.3	1
88	Leaders in Cardiovascular Research: Stefanie Dimmeler. Cardiovascular Research, 2020, 116, e202-e204.	1.8	5
89	Adaptive Immunity in Hypertension. Current Hypertension Reports, 2019, 21, 68.	1.5	71
90	High impact Cardiovascular Research: beyond the heart and vessels. Cardiovascular Research, 2019, 115, e166-e171.	1.8	4

#	Article	IF	CITATIONS
91	Leaders in Cardiovascular Research: Peter Libby. Cardiovascular Research, 2019, 115, e61-e62.	1.8	2
92	Leaders in Cardiovascular Research: Jeroen Bax. Cardiovascular Research, 2019, 115, e109-e110.	1.8	0
93	Human Y Chromosome Exerts Pleiotropic Effects on Susceptibility to Atherosclerosis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2019, 39, 2386-2401.	1.1	36
94	Causal association between periodontitis and hypertension: evidence from Mendelian randomization and a randomized controlled trial of non-surgical periodontal therapy. European Heart Journal, 2019, 40, 3459-3470.	1.0	172
95	New Frontiers in Cardiovascular Research 2019. European Heart Journal, 2019, 40, 2931-2932.	1.0	0
96	T Cells Are Dominant Population in Human Abdominal Aortic Aneurysms and Their Infiltration in the Perivascular Tissue Correlates With Disease Severity. Frontiers in Immunology, 2019, 10, 1979.	2.2	45
97	Leaders in Cardiovascular Research: Thomas Lüscher. Cardiovascular Research, 2019, 115, e125-e126.	1.8	0
98	Medical Misinformation. Circulation, 2019, 139, 571-572.	1.6	29
99	Medical misinformation: vet the message!. Cardiovascular Research, 2019, , .	1.8	3
100	Medical Misinformation. Hypertension, 2019, 73, 506-507.	1.3	1
101	Medical misinformation: vet the message!. European Heart Journal - Cardiovascular Pharmacotherapy, 2019, 5, 62-63.	1.4	0
102	1,2,3,4,6â€Pentaâ€ <i>O</i> â€galloylâ€Î²â€ <scp>d</scp> â€glucose modulates perivascular inflammation and pr vascular dysfunction in angiotensin IIâ€induced hypertension. British Journal of Pharmacology, 2019, 176, 1951-1965.	events 2.7	22
103	Comorbidity burden and clinical characteristics of patients with difficult-to-control rheumatoid arthritis. Clinical Rheumatology, 2019, 38, 2473-2481.	1.0	26
104	A Novel Triple-Cell Two-Dimensional Model to Study Immune-Vascular Interplay in Atherosclerosis. Frontiers in Immunology, 2019, 10, 849.	2.2	25
105	Immune mechanisms of hypertension. Nature Reviews Immunology, 2019, 19, 517-532.	10.6	281
106	Cardio-oncology: a novel platform for basic and translational cardiovascular investigation driven by clinical need. Cardiovascular Research, 2019, 115, 819-823.	1.8	17
107	Medical Misinformation. Circulation: Cardiovascular Imaging, 2019, 12, e008809.	1.3	0
108	Immune cells as targets for cardioprotection: new players and novel therapeutic opportunities. Cardiovascular Research, 2019, 115, 1117-1130.	1.8	125

#	Article	IF	CITATIONS
109	Plan S: In service or disservice to society?. British Journal of Pharmacology, 2019, 176, 753-756.	2.7	3
110	Leaders in Cardiovascular Research: Barbara Casadei. Cardiovascular Research, 2019, 115, e17-e19.	1.8	0
111	Medical Misinformation. Circulation: Heart Failure, 2019, 12, e005869.	1.6	0
112	Medical misinformation: vet the message!. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 83-84.	1.8	1
113	Plan S: in Service or Disservice to Society?. European Heart Journal, 2019, 40, 949-952.	1.0	7
114	Medical Misinformation. Circulation: Cardiovascular Interventions, 2019, 12, e007796.	1.4	0
115	The aorta can act as a site of naÃ⁻ve CD4+ T-cell priming. Cardiovascular Research, 2019, 116, 306-316.	1.8	30
116	When, where, and how to target vascular inflammation in the post-CANTOS era?. European Heart Journal, 2019, 40, 2492-2494.	1.0	13
117	Medical Misinformation. Circulation Genomic and Precision Medicine, 2019, 12, e002439.	1.6	1
118	Medical Misinformation. Circulation: Cardiovascular Quality and Outcomes, 2019, 12, e005496.	0.9	0
119	Medical misinformation: Vet the message!. Heart Rhythm, 2019, 16, 332-333.	0.3	3
120	Medical Misinformation. Journal of Cardiovascular Pharmacology, 2019, 73, 61-62.	0.8	1
121	Th1â€type immune responses to <i>Porphyromonas gingivalis</i> antigens exacerbate angiotensin IIâ€dependent hypertension and vascular dysfunction. British Journal of Pharmacology, 2019, 176, 1922-1931.	2.7	35
122	Diabetes enhances epicardial fat dysfunction. Polish Archives of Internal Medicine, 2019, 129, 733-734.	0.3	2
123	Oxidative stress and inflammatory markers in prediabetes and diabetes. Journal of Physiology and Pharmacology, 2019, 70, .	1.1	186
124	How can the results of the COMPASS trial benefit patients with coronary or peripheral artery disease in Poland?. Kardiologia Polska, 2019, 77, 661-669.	0.3	7
125	Medical Misinformation: Vet the Message!. Anatolian Journal of Cardiology, 2019, 21, 58-59.	0.5	0

0

#	Article	IF	CITATIONS
127	The evolution of Cardiovascular Research Onlife: online and on demand. Cardiovascular Research, 2018, 114, e9-e9.	1.8	7
128	Cardiovascular Research: new challenges and new horizons. Cardiovascular Research, 2018, 114, 1-2.	1.8	11
129	Higher levels of circulating naÃ⁻ve CD8+CD45RA+ cells are associated with lower extent of coronary atherosclerosis and vascular dysfunction. International Journal of Cardiology, 2018, 259, 26-30.	0.8	11
130	Age determines response to anti-TNFα treatment in patients with ankylosing spondylitis and is related to TNFα-producing CD8 cells. Clinical Rheumatology, 2018, 37, 1597-1604.	1.0	8
131	Epigenetics and Immunometabolism in Diabetes and Aging. Antioxidants and Redox Signaling, 2018, 29, 257-274.	2.5	63
132	Diabetes, Hypertension, and Cardiovascular Disease: Clinical Insights and Vascular Mechanisms. Canadian Journal of Cardiology, 2018, 34, 575-584.	0.8	945
133	Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet, The, 2018, 391, 205-218.	6.3	426
134	P2856Predictors of survival in hypertensive patients with left ventricle hypertrophy. European Heart Journal, 2018, 39, .	1.0	0
135	<i>In vivo</i> multiplex molecular imaging of vascular inflammation using surface-enhanced Raman spectroscopy. Theranostics, 2018, 8, 6195-6209.	4.6	56
136	Professor Charalambos Antoniades interviews Professor Tomasz Guzik, incoming Editor-in-Chief of Cardiovascular Research. Cardiovascular Research, 2018, 114, e10-e10.	1.8	0
137	P4783Arterial elastance predicts survival in low risk hypertensive patients. European Heart Journal, 2018, 39, .	1.0	0
138	New heights and hot topics inCardiovascular Research. Cardiovascular Research, 2018, 114, e114-e119.	1.8	3
139	What matters in Cardiovascular Research? Scientific discovery driving clinical delivery. Cardiovascular Research, 2018, 114, 1565-1568.	1.8	10
140	Monocytes M(MP)aking Way for T-Cell Vascular Infiltration. Circulation Research, 2018, 123, 638-640.	2.0	3
141	Microvascular dysfunction in ankylosing spondylitis is associated with disease activity and is improved by anti-TNF treatment. Scientific Reports, 2018, 8, 13205.	1.6	18
142	Pushing the frontiers of cardiovascular biology. Cardiovascular Research, 2018, 114, e22-e22.	1.8	4
143	Hypertension and increased endothelial mechanical stretch promote monocyte differentiation and activation: roles of STAT3, interleukin 6 and hydrogen peroxide. Cardiovascular Research, 2018, 114, 1547-1563.	1.8	121
144	Hypertension: Focus on autoimmunity and oxidative stress. Free Radical Biology and Medicine, 2018, 125, 104-115.	1.3	91

#	Article	IF	CITATIONS
145	Involvement of CD8+ T cell subsets in early response to vascular injury in patients with peripheral artery disease in vivo. Clinical Immunology, 2018, 194, 26-33.	1.4	11
146	High Fat Diet Attenuates the Anticontractile Activity of Aortic PVAT via a Mechanism Involving AMPK and Reduced Adiponectin Secretion. Frontiers in Physiology, 2018, 9, 51.	1.3	51
147	Effects of controlled physical activity on immune cell phenotype in peripheral blood in prehypertension - studies in preclinical model and randomised crossover study. Journal of Physiology and Pharmacology, 2018, 69, .	1.1	1
148	Systemic T Cells and Monocyte Characteristics in Patients with Denture Stomatitis. Journal of Prosthodontics, 2017, 26, 19-28.	1.7	7
149	Perivascular adipose tissue inflammation in vascular disease. British Journal of Pharmacology, 2017, 174, 3496-3513.	2.7	251
150	Vascular transcriptome profiling identifies Sphingosine kinase 1 as a modulator of angiotensin II-induced vascular dysfunction. Scientific Reports, 2017, 7, 44131.	1.6	36
151	Thermographic imaging as alternative method in allergy diagnosis. Journal of Thermal Analysis and Calorimetry, 2017, 127, 1163-1170.	2.0	10
152	Case of Asymptomatic Carotid Artery Stenosis in a Hypertensive Patient. Hypertension, 2017, 69, 985-991.	1.3	3
153	Linking noise to cardiovascular disease pathogenesis. European Heart Journal, 2017, 38, 2850-2852.	1.0	7
154	Rationale, Design and Baseline Characteristics of Participants in the C ardiovascular O utco m es for P eople Using A nticoagulation S trategie s (COMPASS) Trial. Canadian Journal of Cardiology, 2017, 33, 1027-1035.	0.8	133
155	Novel Immune Mechanisms in Hypertension and Cardiovascular Risk. Current Cardiovascular Risk Reports, 2017, 11, 12.	0.8	55
156	Natural killer cells in placentation and cancer: Implications for hypertension during pregnancy. Placenta, 2017, 56, 59-64.	0.7	6
157	Antiâ€atherosclerotic effect of the angiotensin 1–7 mimetic AVE0991 is mediated by inhibition of perivascular and plaque inflammation in early atherosclerosis. British Journal of Pharmacology, 2017, 174, 4055-4069.	2.7	94
158	Oxidative Stress, Inflammation, and Vascular Aging in Hypertension. Hypertension, 2017, 70, 660-667.	1.3	453
159	CD14+CD16++ "nonclassical―monocytes are associated with endothelial dysfunction in patients with coronary artery disease. Thrombosis and Haemostasis, 2017, 117, 971-980.	1.8	58
160	The role of infiltrating immune cells in dysfunctional adipose tissue. Cardiovascular Research, 2017, 113, 1009-1023.	1.8	302
161	PoLA/CFPiP/PCS Guidelines for the Management of Dyslipidaemias for Family Physicians 2016. Archives of Medical Science, 2017, 1, 1-45.	0.4	70
162	Treatment of denture-related stomatitis improves endothelial function assessed by flow-mediated vascular dilation. Archives of Medical Science, 2017, 1, 66-74.	0.4	14

#	Article	IF	CITATIONS
163	Heterogenous treatment effects: secrets for a reliable treat-to-target trial?. Cardiovascular Research, 2017, 113, e18-e20.	1.8	1
164	Polish Forum for Prevention Guidelines on Prophylactic Pharmacotherapy: update 2017. Kardiologia Polska, 2017, 75, 508-511.	0.3	1
165	Endothelial dysfunction is independent of inflammation and altered CCR7 T cell expression in patients with ankylosing spondylitis. Clinical and Experimental Rheumatology, 2017, 35, 844-849.	0.4	6
166	Thermographic assessment of skin prick tests in comparison with the routine evaluation methods. Postepy Dermatologii I Alergologii, 2016, 3, 193-198.	0.4	6
167	Role and analysis of monocyte subsets in cardiovascular disease. Thrombosis and Haemostasis, 2016, 116, 626-637.	1.8	113
168	Role of Tumor Necrosis Factor-α and Natural Killer Cells in Uterine Artery Function and Pregnancy Outcome in the Stroke-Prone Spontaneously Hypertensive Rat. Hypertension, 2016, 68, 1298-1307.	1.3	23
169	Activation of Human T Cells in Hypertension. Hypertension, 2016, 68, 123-132.	1.3	191
170	Role of chemokine RANTES in the regulation of perivascular inflammation, T ell accumulation, and vascular dysfunction in hypertension. FASEB Journal, 2016, 30, 1987-1999.	0.2	185
171	Heterogeneity of peripheral blood monocytes, endothelial dysfunction and subclinical atherosclerosis in patients with systemic lupus erythematosus. Lupus, 2016, 25, 18-27.	0.8	40
172	Macrophages come to mind as keys to cognitive decline. Journal of Clinical Investigation, 2016, 126, 4393-4395.	3.9	11
173	Chemokine RANTES is increased at early stages of coronary artery disease. Journal of Physiology and Pharmacology, 2016, 67, 321-8.	1.1	22
174	Novel methodologies for biomarker discovery in atherosclerosis. European Heart Journal, 2015, 36, 2635-2642.	1.0	174
175	Intima-media thickness and endothelial dysfunction in GCK and HNF1A-MODY patients. European Journal of Endocrinology, 2015, 172, 277-283.	1.9	12
176	Obligatory Role for B Cells in the Development of Angiotensin II–Dependent Hypertension. Hypertension, 2015, 66, 1023-1033.	1.3	185
177	M2 macrophage accumulation in the aortic wall during angiotensin II infusion in mice is associated with fibrosis, elastin loss, and elevated blood pressure. American Journal of Physiology - Heart and Circulatory Physiology, 2015, 309, H906-H917.	1.5	109
178	Malignant hypertension: new aspects of an old clinical entity. Polish Archives of Internal Medicine, 2015, 126, 86-93.	0.3	10
179	Immune Mechanisms in Vascular Disease and Stroke. BioMed Research International, 2014, 2014, 1-2.	0.9	1
180	Letter to the Editor Inflammatory aortic abdominal aneurysm – immunophenotypic characterization of inflammatory infiltrate. Archives of Medical Science, 2014, 6, 1258-1262.	0.4	2

#	Article	IF	CITATIONS
181	Blood Monocyte Heterogeneity and Markers of Endothelial Activation in Ankylosing Spondylitis. Journal of Rheumatology, 2014, 41, 481-489.	1.0	29
182	Blood Monocyte Subsets and Selected Cardiovascular Risk Markers in Rheumatoid Arthritis of Short Duration in relation to Disease Activity. BioMed Research International, 2014, 2014, 1-10.	0.9	20
183	Denture-Related Stomatitis Is Associated with Endothelial Dysfunction. BioMed Research International, 2014, 2014, 1-9.	0.9	23
184	GTP Cyclohydrolase I Gene Polymorphisms Are Associated with Endothelial Dysfunction and Oxidative Stress in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2014, 9, e108587.	1.1	11
185	NADPH Oxidases in Vascular Pathology. Antioxidants and Redox Signaling, 2014, 20, 2794-2814.	2.5	370
186	Characterization of the impairment of the uptake of apoptotic polymorphonuclear cells by monocyte subpopulations in systemic lupus erythematosus. Lupus, 2014, 23, 1358-1369.	0.8	14
187	In Search of the T Cell Involved in Hypertension and Target Organ Damage. Hypertension, 2014, 64, 224-226.	1.3	16
188	"Radical―Link Between Chronic Obstructive Pulmonary Disease and Cardiovascular Disease?. Hypertension, 2014, 63, 444-446.	1.3	4
189	DC isoketal-modified proteins activate T cells and promote hypertension. Journal of Clinical Investigation, 2014, 124, 4642-4656.	3.9	400
190	Functional Implications of Reactive Oxygen Species (ROS) in Human Blood Vessels. , 2014, , 1155-1176.		2
191	Mechanisms of oxidative stress in human aortic aneurysms — Association with clinical risk factors for atherosclerosis and disease severity. International Journal of Cardiology, 2013, 168, 2389-2396.	0.8	108
192	Elevated markers of inflammation and endothelial activation and increased counts of intermediate monocytes in adult survivors of childhood acute lymphoblastic leukemia. Immunobiology, 2013, 218, 810-816.	0.8	27
193	Management of familial heterozygous hypercholesterolemia: Position Paper of the Polish Lipid Expert Forum. Journal of Clinical Lipidology, 2013, 7, 217-221.	0.6	28
194	22-Year-old patient with malignant hypertension associated with primary aldosteronism. Journal of Human Hypertension, 2013, 27, 138-140.	1.0	7
195	Markers of Thrombogenesis and Fibrinolysis and Their Relation to Inflammation and Endothelial Activation in Patients with Idiopathic Pulmonary Arterial Hypertension. PLoS ONE, 2013, 8, e82628.	1.1	19
196	Endothelial function assessment in atherosclerosis. Comparison of brachial artery flow‑mediated vasodilation and peripheral arterial tonometry. Polish Archives of Internal Medicine, 2013, 123, 443-452.	0.3	40
197	Management of familial heterozygous hypercholesterolemia. Position paper of the Polish Lipid Expert Forum. Polish Archives of Internal Medicine, 2013, 123, 7-10.	0.3	1
198	Studies of the T-Cell Angiotensin Receptor Using Cre-Lox Technology. Circulation Research, 2012, 110, 1543-1545.	2.0	9

#	Article	IF	CITATIONS
199	Angiogenesis, stem cells, eNOS and inflammation – the many faces of vascular biology. Thrombosis and Haemostasis, 2012, 108, 801-803.	1.8	1
200	Do we know enough about the immune pathogenesis of acute coronary syndromes to improve clinical practice?. Thrombosis and Haemostasis, 2012, 108, 443-456.	1.8	46
201	Changes in Exercise Capacity and Cardiac Performance in a Series of Patients with Eisenmenger's Syndrome Transitioned from Selective to Dual Endothelin Receptor Antagonist. Heart Lung and Circulation, 2012, 21, 671-678.	0.2	8
202	Vessel wall – where coagulation meets cell biology and immunology. Thrombosis and Haemostasis, 2012, 108, 416-418.	1.8	1
203	Local inflammation is associated with aortic thrombus formation in abdominal aortic aneurysms. Thrombosis and Haemostasis, 2012, 108, 812-823.	1.8	36
204	Targeting NADPH oxidases in vascular pharmacology. Vascular Pharmacology, 2012, 56, 216-231.	1.0	204
205	Novel Therapeutic Approaches in Limiting Oxidative Stress and Inflammation. Current Pharmaceutical Biotechnology, 2012, 13, 2456-2466.	0.9	29
206	Angiotensin-(1-7) receptor Mas agonist ameliorates progress of atherosclerosis in apoE-knockout mice. Journal of Physiology and Pharmacology, 2012, 63, 77-85.	1.1	34
207	Prolactinnot only lactotrophin. A "new" view of the "old" hormone. Journal of Physiology and Pharmacology, 2012, 63, 435-43.	1.1	79
208	Inflammation, Immunity, and Hypertension. Hypertension, 2011, 57, 132-140.	1.3	718
209	ESC Guidelines on the diagnosis and treatment of peripheral artery diseases: Document covering atherosclerotic disease of extracranial carotid and vertebral, mesenteric, renal, upper and lower extremity arteries * The Task Force on the Diagnosis and Treatment of Peripheral Artery Diseases of the European Society of Cardiology (ESC). European Heart Journal, 2011, 32, 2851-2906.	1.0	1,394
210	Rapid, Direct Effects of Statin Treatment on Arterial Redox State and Nitric Oxide Bioavailability in Human Atherosclerosis via Tetrahydrobiopterin-Mediated Endothelial Nitric Oxide Synthase Coupling. Circulation, 2011, 124, 335-345.	1.6	191
211	Mechanisms of increased vascular superoxide production in human varicose veins. Polish Archives of Internal Medicine, 2011, 121, 279-286.	0.3	15
212	Mechanisms of increased vascular superoxide production in human varicose veins. , 2011, 121, 279-86.		11
213	Interleukin 17 Promotes Angiotensin Il–Induced Hypertension and Vascular Dysfunction. Hypertension, 2010, 55, 500-507.	1.3	662
214	Inhibition and Genetic Ablation of the B7/CD28 T-Cell Costimulation Axis Prevents Experimental Hypertension. Circulation, 2010, 122, 2529-2537.	1.6	249
215	Induction of Hypertension and Peripheral Inflammation by Reduction of Extracellular Superoxide Dismutase in the Central Nervous System. Hypertension, 2010, 55, 277-283.	1.3	154
216	Central and Peripheral Mechanisms of T-Lymphocyte Activation and Vascular Inflammation Produced by Angiotensin Il–Induced Hypertension. Circulation Research, 2010, 107, 263-270.	2.0	280

#	Article	IF	CITATIONS
217	Functional Studies of NADPH Oxidases in Human Vasculature. , 2010, , 149-167.		0
218	Regulation of T-cell function by endogenously produced angiotensin II. American Journal of Physiology - Regulatory Integrative and Comparative Physiology, 2009, 296, R208-R216.	0.9	539
219	NADPH Oxidases: Molecular Understanding Finally Reaching the Clinical Level?. Antioxidants and Redox Signaling, 2009, 11, 2365-2370.	2.5	39
220	Is hypertension an immunologic disease?. Current Cardiology Reports, 2008, 10, 464-469.	1.3	72
221	NO and PGI2 in coronary endothelial dysfunction in transgenic mice with dilated cardiomyopathy. Basic Research in Cardiology, 2008, 103, 417-430.	2.5	21
222	Retinopathy in typeÂ2 diabetes mellitus is associated with increased intimaâ€media thickness and endothelial dysfunction. European Journal of Clinical Investigation, 2008, 38, 925-930.	1.7	47
223	GCH1 Haplotype Determines Vascular and Plasma Biopterin Availability in Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 52, 158-165.	1.2	83
224	Calcium-Dependent NOX5 Nicotinamide Adenine Dinucleotide Phosphate Oxidase Contributes to Vascular Oxidative Stress in Human Coronary Artery Disease. Journal of the American College of Cardiology, 2008, 52, 1803-1809.	1.2	249
225	Loss of Extracellular Superoxide Dismutase Leads to Acute Lung Damage in the Presence of Ambient Air. American Journal of Pathology, 2008, 173, 915-926.	1.9	108
226	Importance of the chemokine RANTES in the development of angiotensin IIâ€induced hypertension and vascular dysfunction. FASEB Journal, 2008, 22, 1210.8.	0.2	0
227	Role of the T cell in the genesis of angiotensin II–induced hypertension and vascular dysfunction. Journal of Experimental Medicine, 2007, 204, 2449-2460.	4.2	1,468
228	Plasma Asymmetric Dimethylarginine (ADMA) Is Associated With Retinopathy in Type 2 Diabetes. Diabetes Care, 2007, 30, 2899-2901.	4.3	52
229	Endothelial NF-κB As a Mediator of Kidney Damage. Circulation Research, 2007, 101, 227-229.	2.0	40
230	Role of the Multidrug Resistance Protein-1 in Hypertension and Vascular Dysfunction Caused by Angiotensin II. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 762-768.	1.1	86
231	Implications of Oral Helicobacter pylori for the Outcome of its Gastric Eradication Therapy. Journal of Clinical Gastroenterology, 2007, 41, 145-151.	1.1	37
232	Oxidative stress and hypertension. Journal of the American Society of Hypertension, 2007, 1, 30-44.	2.3	97
233	Perivascular adipose tissue as a messenger of the brain-vessel axis: role in vascular inflammation and dysfunction. Journal of Physiology and Pharmacology, 2007, 58, 591-610.	1.1	118
234	Coronary Artery Superoxide Production and Nox Isoform Expression in Human Coronary Artery Disease. Arteriosclerosis, Thrombosis, and Vascular Biology, 2006, 26, 333-339.	1.1	245

#	Article	IF	CITATIONS
235	Ghrelin Inhibits Vascular Superoxide Production in Spontaneously Hypertensive Rats. American Journal of Hypertension, 2006, 19, 764-767.	1.0	70
236	Inhibition of five lipoxygenase activating protein (FLAP) by MK-886 decreases atherosclerosis in apoE/LDLR-double knockout mice. European Journal of Clinical Investigation, 2006, 36, 141-146.	1.7	88
237	Vascular NADPH oxidases as drug targets for novel antioxidant strategies. Drug Discovery Today, 2006, 11, 524-533.	3.2	199
238	Adipocytokines - novel link between inflammation and vascular function?. Journal of Physiology and Pharmacology, 2006, 57, 505-28.	1.1	291
239	Effects of novel plant antioxidants on platelet superoxide production and aggregation in atherosclerosis. Journal of Physiology and Pharmacology, 2006, 57, 611-26.	1.1	45
240	Measurement of Vascular Reactive Oxygen Species Production by Chemiluminescence. , 2005, 108, 073-090.		37
241	A Myocardial Nox2 Containing NAD(P)H Oxidase Contributes to Oxidative Stress in Human Atrial Fibrillation. Circulation Research, 2005, 97, 629-636.	2.0	367
242	Persistent skin colonization with Staphylococcus aureus in atopic dermatitis: relationship to clinical and immunological parameters. Clinical and Experimental Allergy, 2005, 35, 448-455.	1.4	123
243	Superoxide dismutase activity and expression in human venous and arterial bypass graft vessels. Journal of Physiology and Pharmacology, 2005, 56, 313-23.	1.1	28
244	Systemic Regulation of Vascular NAD(P)H Oxidase Activity and Nox Isoform Expression in Human Arteries and Veins. Arteriosclerosis, Thrombosis, and Vascular Biology, 2004, 24, 1614-1620.	1.1	120
245	Shear Stress Insensitivity of Endothelial Nitric Oxide Synthase Expression as a Genetic Risk Factor for Coronary Heart Disease. Circulation Research, 2004, 95, 841-847.	2.0	279
246	Comparative efficacies and durations of action of phenoxybenzamine, verapamil/nitroglycerin solution, and papaverine as topical antispasmodics for radial artery coronary bypass grafting. Journal of Thoracic and Cardiovascular Surgery, 2003, 126, 1798-1805.	0.4	73
247	Smooth Muscle Cells in Human Atherosclerotic Plaques Express the Fractalkine Receptor CX 3 CR1 and Undergo Chemotaxis to the CX 3 C Chemokine Fractalkine (CX 3 CL1). Circulation, 2003, 108, 2498-2504.	1.6	137
248	Tetrahydrobiopterin-dependent preservation of nitric oxide–mediated endothelial function in diabetes by targeted transgenic GTP–cyclohydrolase I overexpression. Journal of Clinical Investigation, 2003, 112, 725-735.	3.9	281
249	Nitric oxide and superoxide in inflammation and immune regulation. Journal of Physiology and Pharmacology, 2003, 54, 469-87.	1.1	742
250	Mechanisms of Increased Vascular Superoxide Production in Human Diabetes Mellitus. Circulation, 2002, 105, 1656-1662.	1.6	915
251	Nitric Oxide Modulates Superoxide Release and Peroxynitrite Formation in Human Blood Vessels. Hypertension, 2002, 39, 1088-1094.	1.3	225
252	Urinary leukotriene levels are increased during exacerbation of atopic eczema/dermatitis syndrome. Relation to clinical status. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 732-736.	2.7	14

#	Article	IF	CITATIONS
253	Nitric oxide metabolite levels in children and adult patients with atopic eczema/dermatitis syndrome. Allergy: European Journal of Allergy and Clinical Immunology, 2002, 57, 856-856.	2.7	3
254	Mechanisms of superoxide production in human blood vessels: relationship to endothelial dysfunction, clinical and genetic risk factors. Journal of Physiology and Pharmacology, 2002, 53, 515-24.	1.1	110
255	Minimally invasive saphenous vein harvesting: effects on endothelial and smooth muscle function. Annals of Thoracic Surgery, 2001, 71, 1503-1507.	0.7	41
256	Relationship between the G894T polymorphism (Glu298Asp variant) in endothelial nitric oxide synthase and nitric oxide-mediated endothelial function in human atherosclerosis. American Journal of Medical Genetics Part A, 2001, 100, 130-137.	2.4	64
257	Enhanced Superoxide Production in Experimental Venous Bypass Graft Intimal Hyperplasia. Arteriosclerosis, Thrombosis, and Vascular Biology, 2001, 21, 189-194.	1.1	82
258	Nitric Oxide Synthase (nNOS) Gene Transfer Modifies Venous Bypass Graft Remodeling. Circulation, 2001, 104, 1526-1532.	1.6	89
259	Vascular Superoxide Production by NAD(P)H Oxidase. Circulation Research, 2000, 86, E85-90.	2.0	434
260	UltraRapid Communications. Circulation Research, 2000, 86, 1008-1008.	2.0	13
261	Functional Effect of the C242T Polymorphism in the NAD(P)H Oxidase p22phox Gene on Vascular Superoxide Production in Atherosclerosis. Circulation, 2000, 102, 1744-1747.	1.6	223
262	COVID-19: The New Immune Challenge. Frontiers for Young Minds, 0, 8, .	0.8	0